SOUTH SAN FRANCISCO, Calif. / Oct 14, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical Officer Dirk Thye,... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 03, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26 th Annual Global Investment Conference on September 9,... Read More

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline Quince recently initiated pivotal Phase 3 NEAT study, which is currently enrolling and being conducted under U.S. FDA Special Protocol Assessment agreement SOUTH SAN FRANCISCO,... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 13, 2024 / Business Wire / Quince Therapeutics, Inc . (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the second quarter ended June 30, 2024. Dirk Thye, M.D., Quince’s Chief Executive Officer and... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 25, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the first patient has been dosed in the company’s Phase 3 NEAT ( N eurologic E ffects of EryDex on Subjects with A - T ) clinical trial... Read More

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia SOUTH SAN FRANCISCO, Calif. / Jun 03, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease... Read More

SOUTH SAN FRANCISCO, Calif. / May 13, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024. Dirk Thye, M.D.,... Read More

SOUTH SAN FRANCISCO, Calif. / May 06, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 01, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.... Read More

World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company’s lead Phase 3 asset, new indications, and pipeline expansion SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 15, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company’s Board of Directors. “We... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 07, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34 th Annual Healthcare Life... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 04, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 23, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company. Quince’s newly acquired Phase 3 lead asset,... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 28, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that the U.S. Food and Drug Administration (FDA or the “Agency”) has lifted the partial clinical hold on EryDel S.p.A’s Investigational New Drug (IND) application for its lead... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 06, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company’s corporate legal activities and intellectual... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 10, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced that Dirk Thye, M.D., the company’s Chief Executive Officer, will present at the Sidoti Virtual Investor Conference on Thursday, August 17, 2023, at 3:15 p.m. Eastern Time (12:15... Read More

Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission EryDex utilizes autologous intracellular drug encapsulation (AIDE) technology designed for slow release of steroids over several weeks without long-term toxicity typically associated with chronic administration Potential for rapid expansion of EryDex to other... Read More

Offers $1.80 per share in cash plus CVR to receive 85% of the future net proceeds Quince receives as part of the Lighthouse Pharmaceuticals transaction Stock trades below its net cash and investments balance of approximately $2.30 per share Willing to increase cash component of the offer if company can demonstrate that its net cash at closing would be higher than we currently estimate Offer's cash component alone represents... Read More

Criticizes Board's abysmal track record, excessive compensation, and limited stock ownership Calls on Board to abandon any potential acquisitions and instead to liquidate/sell the company Notes stock dropped 75% after company's last acquisition (a related party transaction) Stock trades at approximately 60% of its net cash Closing company would be easy and inexpensive Stock trades below rejected buyout offer of $1.60 per... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 11, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash. Following careful... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 06, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that it has retained MTS Health Partners, L.P. (MTS) as its financial advisor to support Quince’s Board of Directors and management team in the review and evaluation of... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 05, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors (the “Board”) unanimously approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 22, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital. Quince’s Board of Directors, consistent with its fiduciary responsibilities, will... Read More

Offers $1.60 per share in cash Offer represents 90% premium to yesterday's closing price Stock currently trades below its current cash and investments balance of $2.55 per share Company also has other assets including earnouts and NOLs Company is not developing or selling any drugs Offer not contingent on outside financing NEW YORK, NY / ACCESSWIRE / March 21, 2023 / Earlier today Echo Lake Capital issued a letter to the... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today provided an update on the company’s development pipeline and business outlook for 2023. The company intends to prioritize capital resources toward the expansion of its development pipeline through opportunistic in-licensing and acquisition of... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company’s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, former chief executive... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a poster showcasing the broad... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022, in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today presented preclinical data at the 14 th International Conference on Osteogenesis Imperfecta (OI 2022) demonstrating the potential of its novel targeted therapeutic NOV004 to treat fracture in osteogenesis imperfecta (OI) by promoting accelerated increases in bone... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14 th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022),... Read More